Artwork

Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

hVIVO CEO discusses record H1 revenue and strategic expansion

7:53
 
Distribuie
 

Manage episode 439075571 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
hVIVO PLC (AIM:HVO) chief executive Yamin (Mo) Khan speaks with Proactive's Stephen Gunnion about the company's achievements in the first half of 2024, including a 31% increase in revenue, reaching £35.6 million. Khan highlighted the company's record EBITDA of £8.7 million, reflecting a 68% year-on-year growth. He attributed these successes to the opening of the world’s largest human challenge trial facility in Canary Wharf, which includes 50 beds for CL3 level pathogen trials. Khan also spoke about hVIVO’s strategic expansion of service offerings beyond human challenge trials, including laboratory services and patient recruitment via its FluCamp platform. He emphasised the company’s strong order book, valued at £71 million, and its sales pipeline, which includes £40 million worth of opportunities. As hVIVO looks ahead, Khan reiterated the company’s guidance for 2024 revenue of £62 million and an EBITDA margin at the upper end of market expectations. With an optimistic outlook for future growth, hVIVO remains on track to achieve its 2028 target of £100 million. Watch the full interview to learn more about hVIVO’s financial performance, new contracts, and the CEO’s insights into the company's expansion plans. Make sure to visit Proactive's YouTube channel for more insightful interviews, and don't forget to like, subscribe, and hit the notification bell for future content! #hVIVO #HumanChallengeTrials #ClinicalResearch #BiotechGrowth #MoKhan #ClinicalTrials #CanaryWharf #LabServices #FluCamp #RevenueGrowth #HealthcareInnovation #ProactiveInvestors #EBITDA #2024Targets #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

615 episoade

Artwork
iconDistribuie
 
Manage episode 439075571 series 2891889
Content provided by Proactive Investors. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Proactive Investors or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
hVIVO PLC (AIM:HVO) chief executive Yamin (Mo) Khan speaks with Proactive's Stephen Gunnion about the company's achievements in the first half of 2024, including a 31% increase in revenue, reaching £35.6 million. Khan highlighted the company's record EBITDA of £8.7 million, reflecting a 68% year-on-year growth. He attributed these successes to the opening of the world’s largest human challenge trial facility in Canary Wharf, which includes 50 beds for CL3 level pathogen trials. Khan also spoke about hVIVO’s strategic expansion of service offerings beyond human challenge trials, including laboratory services and patient recruitment via its FluCamp platform. He emphasised the company’s strong order book, valued at £71 million, and its sales pipeline, which includes £40 million worth of opportunities. As hVIVO looks ahead, Khan reiterated the company’s guidance for 2024 revenue of £62 million and an EBITDA margin at the upper end of market expectations. With an optimistic outlook for future growth, hVIVO remains on track to achieve its 2028 target of £100 million. Watch the full interview to learn more about hVIVO’s financial performance, new contracts, and the CEO’s insights into the company's expansion plans. Make sure to visit Proactive's YouTube channel for more insightful interviews, and don't forget to like, subscribe, and hit the notification bell for future content! #hVIVO #HumanChallengeTrials #ClinicalResearch #BiotechGrowth #MoKhan #ClinicalTrials #CanaryWharf #LabServices #FluCamp #RevenueGrowth #HealthcareInnovation #ProactiveInvestors #EBITDA #2024Targets #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
  continue reading

615 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință